Oyajobi BO - Search Results

1

Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.

Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, Bauss F, Radl J, Mundy GR. Dallas SL, et al. Among authors: oyajobi bo. Blood. 1999 Mar 1;93(5):1697-706. Blood. 1999. PMID: 10029599 Free article.

2

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, Grubbs B, Zhao M, Chen D, Sherry B, Mundy GR. Oyajobi BO, et al. Blood. 2003 Jul 1;102(1):311-9. doi: 10.1182/blood-2002-12-3905. Epub 2003 Mar 20. Blood. 2003. PMID: 12649140 Free article.

3

Advances in the management of myeloma bone disease.

Shipman CM, Oyajobi BO, Mundy GR. Shipman CM, et al. Among authors: oyajobi bo. Expert Opin Pharmacother. 2005 Dec;6(16):2781-91. doi: 10.1517/14656566.6.16.2781. Expert Opin Pharmacother. 2005. PMID: 16318429 Review.

4

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.

Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B, Mundy GR. Edwards CM, et al. Among authors: oyajobi bo. Blood. 2008 Mar 1;111(5):2833-42. doi: 10.1182/blood-2007-03-077685. Epub 2007 Dec 19. Blood. 2008. PMID: 18094333 Free PMC article.

5

Absence of herpesvirus DNA sequences in the 5T murine model of human multiple myeloma.

Oyajobi BO, Deng JH, Dallas SL, Jenson HB, Mundy GR, Gao SJ. Oyajobi BO, et al. Br J Haematol. 2000 May;109(2):413-9. doi: 10.1046/j.1365-2141.2000.02038.x. Br J Haematol. 2000. PMID: 10848833 Free article.

6

Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.

Oyajobi BO, Mundy GR. Oyajobi BO, et al. Cancer. 2003 Feb 1;97(3 Suppl):813-7. doi: 10.1002/cncr.11133. Cancer. 2003. PMID: 12548580 Free article.

7

Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging.

Oyajobi BO, Muñoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL, Story B, Grubbs B, Armstrong A, Dougall WC, Garrett IR, Mundy GR. Oyajobi BO, et al. Mol Cancer Ther. 2007 Jun;6(6):1701-8. doi: 10.1158/1535-7163.MCT-07-0121. Epub 2007 May 31. Mol Cancer Ther. 2007. PMID: 17541032 Free PMC article.

8

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.

Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Muñoz S, Zhao M, Mundy GR. Oyajobi BO, et al. Br J Haematol. 2007 Nov;139(3):434-8. doi: 10.1111/j.1365-2141.2007.06829.x. Br J Haematol. 2007. PMID: 17910634 Free PMC article.

9

Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.

Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Oyajobi BO, et al. Cancer Res. 2001 Mar 15;61(6):2572-8. Cancer Res. 2001. PMID: 11289133

10

Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo.

Zhao M, Qiao M, Harris SE, Oyajobi BO, Mundy GR, Chen D. Zhao M, et al. Among authors: oyajobi bo. J Biol Chem. 2004 Mar 26;279(13):12854-9. doi: 10.1074/jbc.M313294200. Epub 2003 Dec 29. J Biol Chem. 2004. PMID: 14701828 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters